Polycystic ovary syndrome

Anindita Nandi; Zijian Chen; Ronak Patel; Leonid Poretsky

doi:10.1016/j.ecl.2013.10.003

Polycystic ovary syndrome

Endocrinol Metab Clin North Am. 2014 Mar;43(1):123-47. doi: 10.1016/j.ecl.2013.10.003.

Authors

Anindita Nandi¹, Zijian Chen¹, Ronak Patel¹, Leonid Poretsky²

Affiliations

¹ Division of Endocrinology and Metabolism, Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY 10003, USA.
² Division of Endocrinology and Metabolism, Department of Medicine, Gerald J. Friedman Diabetes Institute, Beth Israel Medical Center, Albert Einstein College of Medicine, 317 East 17th Street, 7th Floor, New York, NY 10003, USA. Electronic address: lporetsk@chpnet.org.

PMID: 24582095
DOI: 10.1016/j.ecl.2013.10.003

Abstract

Polycystic ovary syndrome (PCOS), a heterogeneous and chronic condition, today affects about 5% of women of reproductive age. PCOS is strongly associated with states of insulin resistance and hyperinsulinemia. Risk factors include genetics, metabolic profiles, and the in utero environment. Long-term consequences of PCOS include metabolic complications such as diabetes, obesity, and cardiovascular disease. Dysregulation of insulin action is closely linked to the pathogenesis of PCOS. However, whether insulin resistance is the causative factor in the development of PCOS remains to be ascertained. Moreover, the mechanism by which insulin resistance may lead to reproductive dysfunction requires further elucidation.

Keywords: Insulin resistance; Long-term effects; Polycystic ovary syndrome; Risk factors.

Publication types

Review

MeSH terms

Female
Humans
Insulin Resistance / physiology*
Polycystic Ovary Syndrome* / complications
Polycystic Ovary Syndrome* / etiology
Polycystic Ovary Syndrome* / metabolism
Polycystic Ovary Syndrome* / therapy